CEO stock sale is old news from last week (Barron's just catching up). Motley Fool also picks on EXEL this morning to make a point about Warren Buffet. To me all this means is EXEL is clearly on the radar and there are parties out there looking to get cheap shares by scaring the weak hands. Sorry boys and girls but the EXEL investors know what they have and won't be giving up their shares cheaply as everyone knows where this mid-size, profitable, debt-free, 3 approved products, biotech is going......much more higher from here!! Good try though......
can anyone shed some light on the dumps by the CEO and CFO? Seems weird they'd sell here if this is expected to go higher. Any info on this?
That article about why Buffet wouldn't buy EXEL is probably the dumbest article I've ever seen. Is that really the best they can do to take a shot at EXEL? Oh no, a 90 year old who made the majority of his money decades ago when the internet didn't even exist wouldn't buy the stock (in the opinion of the writer, of course, because none of this is fact). Hilarious. I'm working on my own article: Why Batman wouldn't buy Exel.
Motley Fool and Barron's are surely caring about EXEL!! Only conclusion other than starting to chips away at the $28 today!! Cheers to all longs!!
(6 in favor and 6 against...) Pfizer Announces Outcome of FDA Advisory Committee Meeting for SUTENT® in Patients at High Risk of Recurrent Renal Cell Carcinoma after Surgery
Business Wire Business WireSeptember 19, 2017Comment NEW YORK--(BUSINESS WIRE)--
Pfizer Inc. (PFE) today announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drug Advisory Committee (ODAC) voted 6 in favor and 6 against the benefit-risk profile for SUTENT® (sunitinib) as adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma (RCC) after nephrectomy (surgical removal of the cancer-containing kidney). The role of the Advisory Committee is to provide recommendations to the FDA. The ODAC discussions were based on the supplemental New Drug Application (sNDA) currently under review by the FDA. The FDA decision on whether or not to approve the sNDA is anticipated by January 2018. https://finance.yahoo.com/news/pfizer-announces-outcome-fda-advisory-171500418.html
Pfizer Announces Outcome of FDA Advisory Committee Meeting for SUTENT® in Patients at High Risk of Recurrent Renal Cell Carcinoma after Surgery
Pfizer Inc. today announced that the U.S. Food and Drug Administration’s Oncologic Drug Advisory Committee voted 6 in favor and 6 against the benefit-risk profile for SUTENT® as adjuvant treatment of adult patients at high risk of recurrent renal cel
Where is the CS-3150 data? The 6 or 7 P3 trials are all complete and have been. Is Daiichi keeping them quiet?
Where is CELESTIAL data?
I want to buy my Audi q7 from EXEL made money. So I want EXEL to be at list $60.
Anyone knows how much shares do the CEO and CFO of EXEL still own after the sale?? Appreciate input.
News from ESMO and MS conf should be fully digested as new investors and tutes look to take positions this week before the next leg up. Lets see if we can take out $30 and set a new 52 week high before month end (2 more weeks)!!
Haha. The second I see a negative article posted by Motley Fool, we are headed up!!
Nice strong finish today........btw, if we did have a buyer coming the "rumor" alone would get us to $30-$32 range! In the meantime, steady as she goes and new 52 week high will come soon.....
Chipping away at $27!!
Many said the same thing about Buffet when he said the Internet was way overpriced. Then the Dot.com bubble burst and many lost money while Warren stocks kept growing slow and steady. I think you should heed his advice and not scoff at it.
Should see $28 today
No stopping now!! To the moon and beyond. The weakness on BMY data as outlined by Big M affirms strongly what I posted earlier. Exel will have a free hand in advanced kidney cancer. No competition in 1st line rx. NCNN GUIDELINES updated Cabo as primary rx. Doctors will use Cabo as primary rx ( not waiting for FDA Approval). and doctors know that it is better than pfeizer's Sutent. Normally about 6 months-12 months to update NCNN GUIELINES. With all the confusion and hoopla about BMY data as outlined by Big M , we have no competition till 2021!! ( combo studies that include Cabo!!). We will be bought out way before then. So cheers to all longs. Go pat yourselves on the back for your sound investment, add to your positions if you can, relax and enjoy the nonstopping run. 🍻🍻🍷🍷👏👏
Must read how BMY with held negative data on their RCC trail.
Spotlight – Medical disclosure farrago hits Esmo 2017 Date September 15, 2017 At a time when oncologists are coming under pressure to prescribe checkpoint blockers there should be more – not less – scrutiny over the benefits of these revolutionary drugs. It was therefore surprising that a highly abbreviated version of data from Opdivo’s Checkmate-214 study in renal cancer was allowed to be presented at an Esmo press conference on Sunday morning. Professor Bernard Escudier first revealed the data at this briefing, but the extent to which negative analyses were left out became evident when the meeting heard full results at an evening presidential session. After EP Vantage filed a complaint with Esmo the organisation’s president-elect, Dr Solange Peters, accepted that this might have been a concern. However, she said Esmo did not scrutinise speakers and had no power over what they said: “The speakers are solely responsible for the information they present.” When contacted by EP Vantage Professor Escudier, of the Institut Gustave Roussy, said he was surprised by the suggestion that relevant data were withheld. He said: “I would never withdraw important information. I selected a few slides and, as requested by Esmo, did not present the HR and p values of OS, which by the way are very positive.” The omitted negative subgroups, however, concerned good-prognosis patients – which Professor Escudier says were in the late-breaking abstract – and PD-L1status, which he describes as “really exploratory, totally confusing for all experts, and thus difficult to discuss”. Timeline The timeline of events is crucial. Journalists covering the story for publication on Sunday would only have had Dr Escudier’s 8:15am press conference comments to go on; the presidential session presentation did not start until 6pm, after most major news outlets would have filed and published. Indeed, coverage by respected outlets including Reuters, the American Journal of Managed Care and Endpointsechoed Professor Escudier’s view that Checkmate-214 was practice-changing, but did not mention negative subgroup analyses. True, there were special circumstances around the timing of the data: Checkmate-214 had only been halted for efficacy on September 7, just as Esmo was about to get under way. Naturally all the data and analyses were very fresh, and at the press conference Dr Escudier said some analyses were being held back for the presidential session, and others for even later. EP Vantage’s complaint to Esmo contended that attendees of the press conference were only shown positive survival curves from Checkmate-214, without hazard ratios. Only positive intent-to-treat and intermediate/poor-risk data were presented. No subgroup data were shown to the press conference. When detailed at the subsequent presidential session these revealed that Opdivo plus Yervoy was actually detrimental in favourable-risk patients, and no more effective in PD-L1-negatives, than Sutent (Esmo 2017 – Renal cancer battlefront moves to the front line, September 11, 2017). Not only is it staggering that Sutent control beat active drug with statistical significance, it suggests that Bristol’s combo might only be relevant in the small subgroup of poor-prognosis PD-L1-positives – representing only 20% of all-comers – with no advantage in the majority of patients. At the press conference Professor Escudier stated that Checkmate-214 supported use of Opdivo plus Yervoy “as a new first-line standard-of-care option for patients with advanced renal cell carcinoma” – not in a specific subgroup of such patients. “Nivo/ipi will be the new standard of care in poor/intermediate patients, which represents 80% of the patients,” he told EP Vantagelater. Esmo discussants at the press conference did not critique his data and were highly supportive of the view that these were landmark results that would affect all first-line renal cell carcinoma patients equally. However, they will only have had available what was shown at the press briefing. Element of novelty When on Tuesday EP Vantage asked Esmo’s Dr Peters about the data omissions and partial presentation of Checkmate-214 at the Sunday morning press conference, she said Dr Escudier wanted to keep back data to preserve an element of novelty for the large audience of medical professionals attending the presidential session. An added coincidence was that Exelixis was holding an analyst event half an hour after Sunday’s presidential session presentation started. Exelixis had updated results from Cabosun, its first-line renal cancer study of Cabometyx, which showed an equally strong PFS hazard ratio, 0.48, in the overall population as seen in the best Checkmate-214 subgroup. However, when questioned by EP Vantage at the press conference Dr Escudier was dismissive of Cabosun, calling Checkmate-214 a “large randomised phase III compared with a small randomised phase II.” Later he told EP Vantage that it was not his role to present Cabosun data. Bristol’s own press release detailing Checkmate-214 was highly favourable, omitting negative subgroup analyses. The group told EP Vantage that as this was the first presentation of Checkmate-214 data its release focused on the primary and secondary endpoints. It will clearly have taken legal advice to stay within investor disclosure requirements. The issue has repercussions beyond mere investor relations, however, since renal cancer patients reading Sunday’s coverage would have got an incomplete picture of the potential of Bristol’s combination. Dr Toni Choueiri, the lead investigator of Cabosun, who also participated in Checkmate-214, told EP Vantage: “In this day and age patients have access to Esmo, have access to Twitter, and they want ... nivo/ipi. There is a disconnect between a result like that and what you do [as a doctor] with a patient that calls you today.” Ironically, the events occurred precisely at the time Esmo is trying to counter excessively positive coverage. In a statement on Tuesday the organisation highlighted what it called “an important problem”: that the lay press is twice as likely to report positive results than negative ones. Dr Choueiri said that for good-prognosis patients Checkmate-214 was not the result he would have wanted to see. To contact the writers of this story email Jacob Plieth or Robin Davison in London at firstname.lastname@example.org or follow @JacobPlieth or @RobinDavison2 on Twitter This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: email@example.com EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A. Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.
CEO just sold $11m in stock? 🤑
28+. Strong buy
Nice strong finish and lots to look forward to......happy weekend all
big buy towards close. strong finish. happy weekend to all!